It would be great for you to be right for a change, but I prefer to take a more realistic view that whilst generic nuvaring and E4 will be great for the company, sales will not sky rocket over night.
There is long term value in this company, but I think we are talking longer timelines.
Would-be investors should continue to be cautious about the Mayne Pharma turn around story.
It would be great for you to be right for a change, but I prefer...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.08 |
Change
0.010(0.20%) |
Mkt cap ! $412.7M | |||
| Open | High | Low | Value | Volume |
| $5.13 | $5.15 | $5.08 | $445.2K | 87.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 810 | $5.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.15 | 2033 | 2 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |